What the business is
Innovent develops, makes and sells prescription medicines, mainly in China, for cancer, weight management, cholesterol, eye and immune diseases. TYVYT anchors oncology; BYVASDA and HALPRYZA are biosimilars—biological medicines highly similar to existing drugs, with no meaningful differences in safety or effectiveness. PEMAZYRE and CYRAMZA are partner medicines. Hospitals and distributors are often the immediate buyers. Sales usually follow delivery and customer acceptance, so revenue can precede cash collection.
Product sales usually follow delivery and acceptance; customers typically receive 45–60 days of credit.
Mazdutide launched at RMB2,920 for a four-pen pack; weight-loss treatment is excluded from national reimbursement, China’s public health insurance coverage.
Royalties and related payments were RMB805.8 million in the first half of 2026, reducing sales retained by Innovent.
Takeda’s consideration remained a contract liability at December 2025: money received for work Innovent still owes.
The challenges
Reimbursement and price pressure. NRDL, China’s national list of medicines covered by public health insurance, can expand treatment while negotiated prices compress returns. The 2024 negotiations produced an average price reduction of 63%. TYVYT revenue rose from RMB1,015.9 million in 2019 to RMB2,289.8 million in 2020. Product gross margin fell from 87.7% to 83.6%.
Mazdutide repeat use. GLORY-1 showed 14.01% average weight loss at 48 weeks for the 6mg group, but nausea affected 50.5%. Doctors reported that cost prevented some patients from continuing. The trial did not establish superiority over untested competitors.
Global evidence and rights. China trial success may not satisfy overseas regulators. The US Food and Drug Administration (FDA) declined sintilimab’s lung-cancer application in 2022 and requested another international trial against standard treatment. Takeda shares IBI363 development costs and US profits or losses, while successful global sales do not all accrue to Innovent.
Cash conversion and partner claims. 2025 operating cash benefited by RMB7,636.829 million from increased contract liabilities, cash received before related work was complete. Group margins do not show each product’s manufacturing costs, partner payments and commercial spending.
The numbers
Free cash flow yield — The RMB7,636.829 million increase in collaboration advances raised free cash flow; excluding it lowers the free cash flow yield to 1.5%.
P/E, last 12 months — A RMB472.068 million tax benefit lifts earnings over the last 12 months; excluding it, the price-to-earnings ratio rises to 181.5 times.
Revenue growth accelerated to 51.8% in 2024, then eased to 38.4% in 2025. Net income turned to RMB813.565 million in 2025 after losses in every prior year shown; real free cash flow, computed as cash from operations minus capital spending, lease payments, interest paid and stock pay, reached 68.7% of revenue in 2025. Diluted EPS turned positive at RMB0.47 in 2025; stock pay was RMB662.696 million.
How it earns, and what can hurt it (RMB millions)
What one share gets (RMB per share)
EPS, diluted — In 2024, intangible impairments cost RMB632.574 million; reversing them with reported tax and shares unchanged changes the loss per share to earnings of RMB0.33.
The verdict
Innovent’s weighted forecast points to HK$115.62 by October 2029, hinging on durable product earnings, pipeline progress and cash conversion. Management targets RMB20 billion of product revenue in 2027 and RMB35–40 billion of total revenue in 2030. By 2030, it wants at least five molecules in global Phase III development—large trials testing benefits and risks before approval—plus launches in the United States and Europe.
The weighted price is HK$92.90 in October 2027, a +4% return. It reaches HK$115.62 in October 2029, a +30% return. The probabilities are 35% bear, 50% base and 15% bull. The 2029 cases span HK$39.95 to HK$258.35 against today’s HK$89.05. Trailing P/E is 111.6x and next-twelve-month P/E is 35.0x.
Mazdutide’s affordability, repeat prescriptions and treatment persistence must turn approval into durable sales. Takeda planned to present detailed IBI343 Phase III results at ESMO, the European Society for Medical Oncology, on 23–27 October 2026. Meaningful IBI363 survival benefit during 2028–2029 would strengthen the global pipeline case as partner contributions fade.
Innovent’s upside rests on converting promising medicines into durable earnings despite price pressure, partner obligations and uncertain global evidence.
